That's my thinking. Yes, the new migraine product looks like a huge winner. But the stock is already selling a something like a P/E of 1 (or lower). The price is completely divorced from reality and if it was going to respond to a new product it would already have responded to earnings exceeding the market cap... So, that leaves the acquisition.
With over 1mm shares bought, I think you missed your chance to buy back when the bid at 2.2c was getting hit. I think this is a fundamental or pivotal change in the chart we are seeing. CHRI is now going to head back up where it belongs.